logo
ECG Challenge: Cardiomyopathy and an Irregular Rhythm

ECG Challenge: Cardiomyopathy and an Irregular Rhythm

Medscape3 hours ago
A 67-year-old man with a history of dilated cardiomyopathy and a left ventricular ejection fraction of 40% presents to his primary care provider for a routine physical examination. His vital signs and blood pressure are normal, but he has an irregular pulse.
Figure 1. Courtesy of Philip J. Podrid, MD.
The correct diagnosis is sinus rhythm, PVCs, and echo beats (Figure 2).
Figure 2. Courtesy of Philip J. Podrid, MD.
Discussion
The rhythm is irregular with a repeating grouped beating pattern, with three QRS complexes and a pause. Therefore, the rhythm is regularly irregular. The average rate is 42 beats/min.
The first of three QRS complexes has a normal duration (0.08 sec) and morphology. The axis is physiologically leftward between 0° and -30° (positive QRS complex in leads I and II and negative in lead aVF). This QRS complex is preceded by a P wave (+), which is positive in leads I, II, aVF, and V4-V6. The PR interval is constant (0.16 sec). Therefore, this is a sinus complex. The QT/QTc intervals are normal (420/350 msec).
The second QRS complex (^) is wide (0.14 sec), and it has an unusual morphology not typical for either a left or right bundle branch block. There is positive concordance from V1-V5, although there is an S wave in V6. This QRS complex is not preceded by a P wave. Therefore, this is a PVC.
The third QRS complex is identical to the first and is therefore supraventricular. This QRS complex is preceded by a P wave (*) that is negative in leads II and aVF, and positive in aVR. Therefore, this is not a sinus P wave. Because it is negative in lead aVF, it originates from either the atrioventricular (AV) node (ie, retrograde) or the low part of the atrium. There is a fixed relationship between the PVC and the negative P wave, so it is likely a retrograde P wave resulting from ventriculoatrial (VA) conduction from the PVC. The supraventricular complex that follows the PVC is therefore termed an echo complex.
An echo complex occurs with a preceding QRS complex that is not preceded by a P wave (junctional, ventricular, or paced complex) and is associated with intact VA conduction. Intact VA conduction may lead to retrograde activation of the atrium (retrograde P wave). Given the right timing, this retrograde atrial impulse can then enter the AV node and His-Purkinje system to restimulate the ventricles in an antegrade direction (ie, it echoes back to the ventricles).
Philip Podrid, MD, is an electrophysiologist, a professor of medicine and pharmacology at Boston University School of Medicine, and a lecturer in medicine at Harvard Medical School. Although retired from clinical practice, he continues to teach clinical cardiology and especially ECGs to medical students, house staff, and cardiology fellows at many major teaching hospitals in Massachusetts. In his limited free time, he enjoys photography, music, and reading.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Colossal Biosciences Founders Launch Secret AI Startup
Colossal Biosciences Founders Launch Secret AI Startup

Forbes

time2 minutes ago

  • Forbes

Colossal Biosciences Founders Launch Secret AI Startup

Astromech's landing page. Astromech In the high-stakes world of biotech and de-extinction, Ben Lamm and George Church are household names. The founders of Colossal Biosciences, Lamm and Church are true pioneers of the industry and the company has done what no other bioscience company has done before. They de-extinct the dire wolf, created the controversial woolly mouse and promise to bring the woolly mammoth back from the grave. However, it was discovered earlier this week that a recent, almost silent, filing with the SEC suggests their next frontier is something far more cryptic. A digital breadcrumb has revealed a new, secretive AI startup operating under the name of Astromech. Unearthed from the dry and opaque world of financial documents, a Form D filing from August 12th, 2025 serves as the first undeniable evidence of the new venture. This single, unassuming document, filed with the Securities and Exchange Commission, shows that Lamm and Church have already successfully raised a staggering $30 million for the company. The paperwork lists them as co-founders and places the venture squarely in the technology sector, formally registered in the state of Delaware. The filing is a key that unlocks a treasure chest of questions, but provides frustratingly few answers. The de-extinction duo is notoriously public, so their total silence on this new company—a fourth partnership in recent years—is deafening. What exactly is Astromech? The name itself may be a clue, a nod to the iconic repair droids of the Star Wars universe—compact, automated mechanics like the beloved R2-D2. But what is it they are aiming to repair or navigate? A minimal website—a neon-drenched fever dream that feels like the opening sequence from a Nintendo video game—offers the only other hints. The site is a barebones portal for job seekers, featuring a mysterious, animated logo of a swirling helix of DNA. Underneath this cryptic imagery is a single, powerful mission statement: navigating the code of life. Given Church's foundational work in genomics and synthetic biology, this is more than just a tagline; it's a declaration of intent. Astromech could be attempting to chart a new course in the digital mapping of our biological destiny. The job titles listed on the website only deepen the mystery. They aren't for engineers or biologist, but for roles that sound ripped from a sci-fi novel: "Synthetic Data Generation Lead," "Multi-Agent Coordinator," "Regulatory Genomics Specialist," 'Emergent Behavior Analyst" and "Robotics Specialized Physical Trainer." These aren't just jobs; they're clues, each one a piece of a larger, still-unseen puzzle pointing to a deeply complex project in advanced AI. When reached for comment, Lamm and a spokesperson for Colossal had a stark, uncharacteristic "no comment," a phrase that only adds more fuel to the fire. Whatever Lamm and Church are building, they want to keep it in the shadows for now, leaving the rest of the world to wonder: are they building the ultimate co-pilot for biology, or are they laying the groundwork for something bigger? MORE FROM FORBES Forbes The Science Of De-Extinction Is Providing Hope For Nature's Future By Emma Kershaw Forbes This Female Scientist Brought The Dire Wolf Back From Extinction By Emma Kershaw Forbes Billionaire Eugene Shvidler Revealed As The Artist Behind ES23 By Emma Kershaw

FACT FOCUS: A look at RFK Jr.'s misleading claims on US dietary guidelines and Froot Loops
FACT FOCUS: A look at RFK Jr.'s misleading claims on US dietary guidelines and Froot Loops

Yahoo

time30 minutes ago

  • Yahoo

FACT FOCUS: A look at RFK Jr.'s misleading claims on US dietary guidelines and Froot Loops

The food pyramid that once guided Americans' diets has been retired for more than a decade, but that has not stopped President Donald Trump's health secretary, Robert F. Kennedy Jr., from regularly criticizing the concept. He often highlights the pyramid, misrepresenting dietary standards and criticizing health initiatives of the Biden administration. Such claims were featured in a video aired Tuesday, before his appearance on Fox News' 'Jesse Watters Primetime.' Here's a closer look at the facts. KENNEDY: 'The dietary guidelines that we inherited from the Biden administration were 453 pages long. They were driven by the same commercial impulses that put Froot Loops at the top of the food pyramid." THE FACTS: The original food pyramid did not mention any specific products. But at the very top, it recommended that oils, fats and sugar be consumed 'sparingly.' Grains such as bread, cereal, rice and pasta were on the bottom tier, where six to 11 portions a day were recommended. The current dietary guidelines are 164 pages long, not 453. They were released in December 2020 during Trump's first term, along with a four-page executive summary. A scientific report used to develop the dietary guidelines is published every five years by an advisory committee. The latest report, released in December by the Biden administration, is 421 pages long. Trump's first administration released an 835-page scientific report in July 2020 that informed the current guidelines. 'The dietary guidelines include several documents, including a scientific report which summarizes the scientific evidence supporting the dietary guidelines,' said Laura Bellows, an associate professor of nutritional sciences at Cornell University. 'It can be long due to the comprehensive nature of the document. That said, these findings are distilled down into concise guidelines that are foundational to the creation of consumer information and educational materials.' Experts said that Froot Loops, a breakfast cereal, would have fallen into multiple categories under the pyramid concept, offering vague guidance to consumers. 'It's a bit trickier than just one grouping,' Bellows said in an email. She said Froot Loops 'would fall more in foods that we should 'moderate' ... but does contribute to the grain group.' The cereal is high in sugar, she added, but does have fiber and other key nutrients. The Agriculture Department introduced an updated pyramid guide in 2005 that incorporated new nutritional standards. It retired the pyramid idea altogether in 2011 and now uses the MyPlate concept, which stresses eating a healthy balance of different foods based on factors such as age and sex. MyPlate recommends making half of the grains one eats in a day whole grains and cutting back on added sugars. Similar to the food pyramid, this puts Froot Loops, which has whole grains and added sugars, in both categories. 'MyPlate, not the Food Pyramid, has been the visual graphic for the US Dietary Guidelines since 2011,' said Bellows. 'So, referring to the 'top of the pyramid' is a dated reference.' Kennedy's other criticism of Froot Loops has focused primarily on its manufacturer's use of artificial dyes to enhance its color. He has made getting rid of artificial colors in foods an important part of his 'Make America Healthy Again' plan. Asked for comment on Kennedy's remarks, the Health and Human Services Department said work is on track to release the final 2025–2030 Dietary Guidelines for Americans. The agency said Kennedy is committed to ensuring those guidelines 'are grounded in gold-standard science and reflect a clear focus on healthy, whole, and nutritious foods.' ___ Find AP Fact Checks here:

Achieve Life Sciences Inches Closer To FDA Nod For First New Quit-Smoking Drug In 20 Years
Achieve Life Sciences Inches Closer To FDA Nod For First New Quit-Smoking Drug In 20 Years

Yahoo

time30 minutes ago

  • Yahoo

Achieve Life Sciences Inches Closer To FDA Nod For First New Quit-Smoking Drug In 20 Years

Achieve Life Sciences Inc. (NASDAQ:ACHV) is moving closer to a pivotal moment as it seeks FDA approval for cytisinicline, a potential first new smoking cessation therapy in nearly two decades, positioning the company for a high-stakes commercial launch in 2026. In a vote of confidence for the late-stage specialty pharmaceutical company's pipeline with a focus on smoking health and nicotine dependence, HC Wainwright has initiated coverage on Achieve Life Sciences with a Buy rating and a $12 price forecast. In June, Achieve Life Sciences submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for cytisinicline for nicotine dependence for smoking cessation in cytisinicline NDA is supported by a combination of efficacy and well-tolerated safety results from two Phase 3 trials, ORCA-2 and ORCA-3, which evaluated cytisinicline for smoking cessation. In both studies, cytisinicline administered for 6 or 12 weeks, alongside standard behavioral support, demonstrated significantly greater abstinence rates by the end of treatment and long-term abstinence through week 24 compared to placebo. The company has also included safety data on over 300 participants with at least six months of cumulative cytisinicline exposure. In June, the company raised around $45 million to fund continued advancement of cytisinicline through potential FDA marketing approval of cytisinicline and for working capital and general corporate purposes. The company expects the funding to provide runway into the second half of 2026. Analyst Brandon Folkes says, 'With the New Drug Application (NDA) now submitted, and a potential FDA approval and commercial launch in 2026, we view the next 12 to 18 months as a period of potential significant value inflection for ACHV stock.' Achieve Life Sciences' shares undervalue the commercial potential of cytisinicline, given the shortcomings of current therapies, rising smoking and vaping rates, and its superior efficacy and tolerability versus Pfizer Inc.'s (NYSE:PFE) Chantix (varenicline) and generics. Folkes sees tolerability as a key edge for cytisinicline, noting varenicline's side effects have limited its use. He argues that Achieve Life Sciences' valuation fails to capture the strong NDA data or the sizable market opportunity, where peak sales could far exceed the company's current worth. According to an investor note from Folkes, a rational pricing strategy for cytisinicline, potentially ranging from $500 to $3,000 per month, could be justified by the significant health economic costs associated with smoking. Cytisinicline could become the first FDA-approved smoking cessation therapy in nearly 20 years, with a U.S. launch expected in 2026. Its differentiated profile, flexible dosing, and broad adoption potential position it well in a $13 billion global market. Before its withdrawal, Pfizer's Chantix generated nearly $1 billion annually in U.S. sales, highlighting the sizable opportunity relative to Achieve's current valuation. Price Action: ACHV stock is trading higher by 14.92% to $2.97 at last check Thursday. Image via Shutterstock Latest Ratings for ACHV Date Firm Action From To Oct 2021 Alliance Global Partners Initiates Coverage On Buy Jun 2021 Oppenheimer Initiates Coverage On Outperform Sep 2020 Lake Street Initiates Coverage On Buy View More Analyst Ratings for ACHV View the Latest Analyst Ratings Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Achieve Life Sciences Inches Closer To FDA Nod For First New Quit-Smoking Drug In 20 Years originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store